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surgeryAbstract Objective: To evaluate the effects of oral nifedipine as pretreatment, quality of surgical
ﬁeld and amount of hypotensive agent during functional endoscopic sinus surgery (FESS) under
general anesthesia.
Methods: Sixty patients ASA I or II scheduled for FESS were randomly allocated into two equal
groups. Oral nifedipine 20 mg was given one hour before induction of anesthesia (nifedipine) group
and placebo. In the other group (control), all the patients received standard anesthesia and moni-
toring. Nitroglycerin (GTN) was administrated in a dose of 2 lg/kg/min after induction of anesthe-
sia till it achieved a target mean arterial blood pressure (MAP) of 50–60 mmHg, followed by a
continuous i.v. infusion (1 lg/kg/min) intraoperative when needed. Hemodynamic variables were
recorded at baseline preoperatively, intraoperatively and till the end of operation. The surgical ﬁeld
score was assessed by average category scale (ACS) and intraoperative blood loss and amount of
GTN was estimated. Emergence time and total recovery from anesthesia (Aldrete score P9) were
recorded.
Results: There were no statistically signiﬁcant differences between two groups with respect to the
amount of blood loss and scores for a bloodless surgical ﬁeld. Emergence time and time needed to
achieve 9 of modiﬁed Aldrete score were signiﬁcantly shorter in Control group than nifedipine
group (4.46 ± 1.25 min and 7.46 ± 2 min versus 8 ± 1.62 min and 9.5 ± 2.41 min, respectively)
(P< 0.01). MAP during hypotensive period showed no statistically signiﬁcant difference
(p> 0.05) but at 5 and 10 min after stoppage of hypotensive anesthesia, at the end of surgery
and after recovery, MAP was signiﬁcantly lower in nifedipine group than Control group
(p< 0.01). Heart rate (HR) during hypotensive period showed no statistically signiﬁcant difference
(p> 0.05). At 5 and 10 min after stoppage of hypotensive anesthesia, at end of surgery and after
recovery, HR was signiﬁcantly lower in nifedipine group than Control group (p< 0.001). The
amount of GTN used in nifedipine group was signiﬁcantly lower than Control group (p< 0.001).
292 A. Hassanein, M. TalaatConclusion: Administration of a single preoperative dose of nifedipine (20 mg) can signiﬁcantly
reduce the blood loss during FESS and improves the visualization of the operative ﬁeld and it also
lowers the amount of GTN needed to achieve target hypotension.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
The introduction of functional endoscopic sinus surgery
(FESS) associated with improved surgical dissection due to
enhanced illumination and visualization of surgical ﬁeld, but
impaired visibility due to excessive bleeding may present a
major complication has been reported for FESS under general
anesthesia [1]. Controlled hypotension is deﬁned as a reduction
in mean arterial blood pressure to 50–60 mmHg in normoten-
sive subject [2]. Many advantages in controlled hypotension
for FESS include reduction in blood loss and improved quality
of surgical ﬁeld. Multiple agents have been used to achieve
controlled hypotension e.g., magnesium sulfate, vasodilators
(sodium nitroprusside), nitroglycerine, high doses of potent
inhaled anesthetics, and beta adrenergic antagonist [3–5].
Although there are numerous approaches to provide con-
trolled hypotension, isoﬂurane has been an integral part of
many reports, and isoﬂurane lends itself particularly well to
the technique of controlled hypotension because of its favor-
able effects on the systemic and cerebral circulation [6–8].
Nitroglycerin is an organic nitrate that acts principally on
venous capacitance vessels to produce peripheral pooling of
blood and decrease cardiac ventricular wall tension. As the
dose of nitroglycerin is increased, there is relaxation of the
arterial vascular smooth muscle. The most common clinical
use of nitroglycerin is either sublingual or intravenous admin-
istration for the treatment of angina pectoris due to either
atherosclerosis of coronary arteries or intermittent vasospasm
of these vessels, and also to achieve hypotension by infusion
[5]. Nifedipine is a potent vasodilator, which relaxes vascular
smooth muscle probably by its inhibitory effect on the trans-
membrane inﬂux of calcium, and it is very effective in the treat-
ment of severe hypertension and hypertensive emergency.
When the conventional form of nifedipine (soft capsule con-
taining 10 mg of dissolved nifedipine) was administered orally,
there was a rapid hypotensive effect occurring maximally at 1 h
after administration and disappearing within 7 h [9]. The ratio-
nale behind using oral nifedipine as an agent for inducing
hypotension in our study is to induce gradual smooth hypoten-
sion without rapid swing in BP by IV hypotensive agents The
current study was designed to evaluate the effect of oral
nifedipine on the hemodynamic changes, the quality of the
operative ﬁeld, blood loss and the amount of nitroglycerine
used in patients undergoing FESS under general anesthesia.2. Methods
A prospective, randomized, single blinded study was done in
Minia University Hospital, during the period from October
2012 to November 2013. After obtaining the informed consent
from patients and approval of the local ethical committee,
sixty ASA physical status I or II patients aging 18–55 years
were scheduled for elective FESS. All patients had bilateralnasal polyposis with opacity of most paranasal sinuses. We
exclude patients with recurrent sinus surgery, history of hyper-
tension, coronary artery diseases, patients with coagulopathies
or receiving drugs inﬂuencing blood coagulation, renal, hep-
atic or cerebral insufﬁciency, morbid obese patients, patients
with neuromuscular diseases, pregnancy, and patients with
prior treatment with calcium channel blockers or beta block-
ers. All surgical procedures were done by the same surgeon,
and he was blinded to the hypotensive agent used. The patients
were examined clinically and investigated by ECG, chest X-ray
and laboratory tests.
Sample size calculation was based on our primary endpoint
of keeping the mean arterial pressure (MAP) between 50 and
60 mmHg, while the normal MAP ranged between 70 and
105 mmHg. For this purpose, a difference of 20 mmHg in
MAP between study and control groups was deemed clinically
relevant. The calculation determined that 60 patients (30 in
each group) would be required for a study with a power of 1
and an alpha of 0.05 set for signiﬁcance. The study design
was parallel grouping; each patient was randomly assigned
to either receive oral nifedipine 20 mg (Epilat 10 mg capsules,
Eipico Pharmaceuticals, EGYPT) (n= 30) or Placebo
(n= 30), receiving placebo one hour before induction of anes-
thesia by sips of water, the placebo was identical to nifedipine
capsules and prepared by the pharmacy to maintain double
blind study, and an appropriate code number was assigned
to each patient, with an allocation ratio of 1:1. Patients were
randomized in block size of 4 to either receive oral nifedipine
20 mg or placebo. Patients were assigned to the next sequence
at the time of surgery. It was impractical to blind the
anesthesiologists.
In the operating room 500 ml lactated Ringer’s solution i.v.
infusion was started in all patients and an intra-arterial line
was inserted under local anesthesia in the radial artery for
direct measurement of arterial blood pressure. One hour pre-
operative in the recovery room the patient connected to con-
tinuous routine monitoring included ECG, pulse oximetry
and invasive blood pressure were measured using (Spacelabs;
model 90364, USA). All patients were premedicated with IV
midazolam 0.05 mg/kg and fentanyl 1 lg/kg. Patients received
standard anesthetic technique with propofol 2 mg/kg, and
intubation was facilitated with atracurium 0.5 mg/kg with suit-
able sized cuffed tube. Anesthesia was maintained with isoﬂu-
rane 1–3% and neuromascular blocker was atracurium with
incremental dose 0.15 mg/kg every 25 min IV, respiration
was controlled with tidal volume 6–9 ml/kg and respiratory
rate 12–15 cycle/min, and the tidal volume used was mostly
guided by the end tidal CO2 (between 33 and 36 mmHg)
(Drager medical AG/COKGaA; model 23542, Germany).
Patients were placed in a 15 reverse Trendlenburg position
to improve venous drainage, and cottonoids soaked with
epinephrine in a concentration of 1:100.000 were inserted into
the nasal cavity and in between the polyps to reduce blood
loss. Nitroglycerin (GTN) (Nitronal aqueous, Global Napi
Table 1 Patient demographic and operative characteristics.
Characteristics Nifedipine
(N= 30)
Control
(N= 30)
P-value
Age (years) 37(19–56) 32(20–52) 0.38
35.1 ± 8 37 ± 9
Gender (M/F) 16/14 18/12 0.43
Weight (kg) 68(31–99) 51(52–103) 0.27
70 ± 15.7 73.9 ± 11.8
ASA (I/II) 14/16 17/13 0.43
Duration of surgery (min) 62(62–124) 51(66–117) 0.60
90 ± 15.3 92 ± 12.9
Amount of blood loss (ml) 110(80–190) 80(90–170) 0.70
129.6 ± 25.9 132 ± 20
Amount of
Nitroglycerine (mg)
3(0–9.5) 16.5(8–30) 0.0001a
3.3 ± 3.4 16 ± 6.4
Data are expressed as median (range) and mean ± standard devi-
ation or number.
a Signiﬁcant difference.
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40 ml of 5% dextrose (1 ml of this solution containing 0.2 mg
of GTN). The hypotensive agent (GTN infusion) was given
after the induction of anesthesia intravenously by using a syr-
inge pump (Pilote A2 10 CCIs; model 36590, France) when
MAP is above 60 mmHg, but not given when MAP is less than
65 mmHg, GTN infusion was started with a rate of
2 lg/kg/min and then decreased to 1 lg/kg/min to maintain
the target level of MAP ranged between 55 and 65 mmHg,
when MAP becomes less than 55 mmHg we stop GTN, and
when MAP persists below 55 mmHg more than 5 min, reduc-
tion in inhalational anesthetic and rapid iv ﬂuids administered
to the patient, then incremental low doses of ephedrine were
given when needed. At the end of the operation, the hypoten-
sive agent was stopped before packing the nose and the resid-
ual effect of atracurium was reversed by neostigmine in a dose
of 0.04 mg/kg and atropine sulfate in a dose of 0.02 mg/kg.
Extubation was carried out when adequate tidal volume and
good cough reﬂex were observed. The patients were transferred
to the recovery room and assessed for any side effects associ-
ated with induction or during maintenance of anesthesia or
during recovery such as persistent hypotension, rebound
hypertension or any excessive nasal bleeding were recorded
and compared in both groups.
2.1. Measured parameters
Assessed parameters include the following: (1) hemodynamics
(heart rate, mean arterial blood pressure, and O2 saturation)
was recorded preoperatively as a baseline, postinduction,
postintubation every minute for 5 min and intraoperative
every 15 min till the end of operation; (2) amount of blood loss
was measured from the suction apparatus and number of com-
pletely socked gauzes (10–15 ml blood); (3) quality of the surgi-
cal ﬁeld: by using average category scale for the assessment of
surgical ﬁeld: 0 = no bleeding, 1 = slight bleeding – no suc-
tioning of blood required, 2 = slight bleeding – occasional suc-
tioning required. Surgical ﬁeld not threatened, 3 = slight
bleeding – frequent suctioning required, bleeding threatens
surgical ﬁeld a few seconds after suction is removed, 4 = mod-
erate bleeding – frequent suctioning required, bleeding threat-
ens surgical ﬁeld directly after suction is removed, 5 = sever
bleeding – constant suctioning required, bleeding appears fas-
ter than can be removed by suction, surgical ﬁeld severely
threatened and surgery not possible. The ideal category scale
values for surgical conditions were predetermined to be two
and three, the surgeon assessed the quality of surgical ﬁeld
by category scale adopted from that of [10]; (4) total amount
of hypotensive agent (GTN) for every patient in both groups;
(5) emergency time, is the time between the discontinuation
of anesthetics to response of eye opening to verbal command
[11]; (6) recovery character by measuring time to reach score
9 of modiﬁed Alderat score [12].
2.2. Statistical analysis
The statistical analysis was carried using a statistical package
(SPSS, version 0.11. interface). Descriptive and analytical
statistics were performed. Numerical data were presented as
mean ± standard deviation (±SD). Paired t-test was used to
compare parametric data inside the group and unpairedt-test between the groups. Rank test Mann Whitney U-test
was used to compare nonparametric data between the two
groups and Wilcoxon test inside the group. Categorical data
were presented as numbers and percent and Chi square test
was used to compare group of categorical data. A P-value
was calculated and considered to be signiﬁcant if <0.05.
3. Results
Sixty patients ASA I and II patients (26 females and 34 males)
undergoing FESS were included (control, n= 30; nifedipine,
n= 30). There were no statistically signiﬁcant differences
between two groups with respect to patient demographic and
operative characteristics (age, gender, weight, ASA, duration
of surgery and amount of blood loss) (p> 0.05) (Table 1). The
amount of nitroglycerine used in nifedipine group was signiﬁ-
cantly lower than Control group (p< 0.001); 12 patients
(40%) of nifedipine group achieved hypotension without the
need for GTN, and the remaining 18 patients (60%) of this group
achieved hypotension with signiﬁcant low amount of GTN.
Scores for a bloodless surgical ﬁeld using the average cate-
gory scale (ACS) (Table 2) during hypotensive period
(MAP= 55–65 mmHg) were low in both groups; there was
no signiﬁcant difference in scores between both groups. The
median range of scores was 2 (1–3) in both groups. No patients
presented with excessive blood loss. Emergence time and time
needed to achieve >9 of modiﬁed Aldrete score (Table 3) were
signiﬁcantly shorter in Control group than nifedipine group
(4.46 ± 1.25 min and 7.46 ± 2 min versus 8 ± 1.62 min and
9.5 ± 2.41 min, respectively) (P< 0.01).
Regarding measurements of mean arterial blood pressure
(MAP) (Fig. 1), nifedipine group showed no statistically
signiﬁcant difference when compared to control group at
basal measurement (92.73 ± 4.77 vs 92 ± 3.84, P= 0.51),
after induction (80.63 ± 5.17 vs 78.90 ± 5.47, P= 0.21) and
during hypotensive period (59.33 ± 3.23 vs 60.20 ± 3.17,
P= 0.29), while MAP in nifedipine group was signiﬁcantly
lower than control group at 5 min after HA (hypotensive
Table 3 Recovery characteristics.
Recovery characteristics
(min)
Nifedpine
(N= 30)
Control
(N= 30)
P-value
Emergence time 7(4–11) 5(2–7) 0.0001a
8 ± 1.62 4.46 ± 1.25
Time to modiﬁed Alderet
score >9
9(5–14) 9(2–11) 0.001a
9.5 ± 2.41 7.46 ± 2
Data are expressed as median (range) and mean ± standard
deviation.
a Signiﬁcant difference.
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Figure 1 Mean values of mean arterial blood pressure (mmHg).
HA: hypotensive anesthesia.
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294 A. Hassanein, M. Talaatanesthesia) (62.96 ± 3.81 vs 80.73 ± 5.89, P< 0.001), 10 min
after HA (66.10 ± 4.38 vs 81.86 ± 5.11, P< 0.001), at end of
surgery (76.56 ± 3.85 vs 85.80 ± 5.46, P< 0.001) and after
recovery (80.73 ± 5.89 vs 83.56 ± 4.19, P= 0.03). Two
patients of nifedipine group needed ephedrine 5 and 10 mg
to elevate MAP above 55 mmHg.
Regarding measurements of heart rate (HR) (Fig. 2),
nifedipine group showed no statistically signiﬁcant difference
when compared to control group at basal measurement
(85.60 ± 2.60 vs 85.16 ± 3.20, P= 0.56), after induction
(70.23 ± 5.67 vs 70 ± 5.81, P= 0.87) and during hypotensive
period (72.36 ± 5.68 vs 71.70 ± 6.24, P= 0.66), while HR in
nifedipine group was signiﬁcantly lower than control group at
5 min after HA (77.13 ± 4.09 vs 67.30 ± 4.45, P< 0.001),
10 min after HA (77.56 ± 4.65 vs 69.33 ± 3.75, P< 0.001),
at end of surgery (75.43 ± 5.96 vs 71.56 ± 5.90, P= 0.01)
and after recovery (73.33 ± 5.58 vs 68.13 ± 4.29, P< 0.001).
4. Discussion
During FESS, nasal and the sinus mucosa are very vascular
and bleed easily, which would interfere with the visualization
of the surgical ﬁeld through the endoscope, and this could
result in inadvertent tissue injury leading to adhesions and
scarring and even severe complications such as orbital and
brain injury [13–17]. A number of techniques/agents have been
advocated to achieve hypotension during FESS. Among the
pharmacological agents nifedipine was chosen as it is a
vasodilator. We examined the use of nifedipine 10 mg in 3 pilot
cases before starting in the study, but we noticed minimal
reduction in MAP, and then we decided to examine nifedipine
20 mg. The result of our study showed that oral nifedipine
(20 mg) one hour before induction of anesthesia markedly
reduces the amount of GTN required to decrease MAP during
FESS by 80% used in control group (3.3 ± 3.4 mg in nifedip-
ine versus 16 ± 6.4 mg in control) These ﬁndings conﬁrm a
previous study by Ahmad1 et al. they investigated the pharma-
cokinetic of nifedipine in healthy adult male human volunteers
which showed that use of oral nifedipine reduced MAP [18], is
also in agreement with our study, and Imai et al. examined the
effect of nifedipine in essential hypertensive patients, when the
conventional form of nifedipine (soft capsule containing 10 mg
of dissolved nifedipine) was administered orally, there was aTable 2 Scores for bloodless surgical ﬁeld (average category
scale).
Time of hypotensive
anesthesia (min)
Nifedipine
(N= 30)
Control
(N= 30)
P-value
15 2(1–3) 2(1–3) 0.63
1.86 ± 0.57 1.80 ± 0.61
30 2(1–3) 2(1–3) 0.67
1.90 ± 0.54 1.96 ± 0.61
45 2(1–3) 2(1–3) 0.55
2.03 ± 0.66 2.13 ± 0.68
60 2(1–3) 2(1–3) 0.82
2.26 ± 0.63 2.23 ± 0.62
Data are expressed as median (range) and mean ± standard devi-
ation. Mann–Whitney test was used.
Figure 2 Mean values of heart rate (Bpm). HA: hypotensive
anesthesia.rapid hypotensive effect occurring maximally at 1 h after
administration and disappearing within 7 h [9]. The probable
mechanism of reducing blood pressure by promote vasodilator
activity (and reduce blood pressure) by reducing calcium inﬂux
into vascular smooth muscle cells by interfering with voltage-
operated calcium channels (and to a lesser extent receptor-
operated channels) in the cell membrane [23]. The study by
Puri and Batra showed that administration of nifedipine
before induction, can reduce arterial pressure but not HR in
responses to laryngoscopy and intubation [19], and this
coincides with our results but signiﬁcant tachycardia was not
recorded in the study group may be due to midazolam and fen-
tanyl premedication; also, Kale and colleagues showed that
oral nifedipine 10 mg is a useful pretreatment to prevent the
pressor response to laryngoscopy and tracheal intubation in
Oral nifedipine as a premedication for induced hypotention 295patients with coronary artery disease [20]. Nitroglycerin
induced hypotension is related primarily to a direct effect of
the drug on vascular smooth muscle. Both resistance and
capacitance vessels are dilated, but the effect on the veins is
predominant [21]. In the study by Nabil and Fahmy, nitroglyc-
erin offers certain advantages over sodium nitroprusside. It
produced a smooth and gradual decrease in blood pressure,
and it is easy to control the dose and blood pressure response
with minimal danger of producing severe hypotension [22]. In
the present study, it is evident that patients receiving oral
nifedipine had a nonsigniﬁcant difference regarding surgical
ﬁeld and amount of blood loss as compared to patients receiv-
ing placebo, and the amount of GTN used in nifedipine group
was 20% of total amount of GTN used in control group to
induce hypotension (p< 0.001), 12 patients (40%) of nifedip-
ine group achieved hypotension without the need for GTN,
this is explained by the fact that nifedipine produces vasodi-
latation, resulting in lower blood pressure and thereby decreas-
ing blood loss at the surgical site and improving the quality of
surgical ﬁeld. In our study, the recovery time and time to reach
Aldrate score 9 were signiﬁcantly higher than control group,
this may be explained by delayed return of skeletal muscle
power under effect of nifedipine as calcium channel blockers
augment the effect of nondepolarizing muscle relaxant.
In conclusion, this study has demonstrated that administration
of a single preoperative dose of nifedipine (20 mg) can sig-
niﬁcantly reduce the blood loss during FESS and improve
the visualization of the operating ﬁeld and it also lowers the
amount of GTN needed to achieve hypotensive anesthesia.
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